OssDsign receives extended FDA approval

OssDsign continues to reap success with the bone graft Catalyst. The company recently announced that it has reached the milestone of 2,000 treatments in the US and, just the other day, the FDA expanded its market approval. The latter opens the door to a lucrative market segment and thus, says CEO Morten Henneveld, the FDA decision is one of the most important events in the company’s history.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/09/ossdsign-receives-extended-fda-approval/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se